Gracell Biotechnologies Inc

Gracell Biotechnologies Inc is a Chinese clinical-stage biopharmaceutical company focused on developing innovative and effective cell therapies. Its goal is to create potential treatments for various cancers and autoimmune disorders, aiming to improve patient outcomes and survival rates. Operating within the biotechnology sector, Gracell Biotechnologies Inc is a wholly owned subsidiary of AstraZeneca Plc, following its acquisition to support AstraZeneca's oncology and cell therapy goals. Its approach involves developing next-generation CAR-T and TCR-T cell programmes and other related pioneering technologies. Keep up to date on the latest share price changes by adding GRCL stock to your eToro watchlist. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.